AstraZeneca AZN
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 21st percentile, 5-year average 90.6x
#2025 of 2972 stocks by PE (1 = cheapest)
Above its usual level · 61st percentile, 5-year average 5.7x
#4502 of 5311 stocks by PB (1 = cheapest)
Around its usual level · 52nd percentile, 5-year average 4.7x
#3849 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 5.76 | – | 5.66 | 61% (pricier than usual) | #4502 of 5311 (1 = cheapest) |
| PE | 27.94 | 21.93 | 90.60 | 21% (cheaper than usual) | #2025 of 2972 (1 = cheapest) |
| PS | 4.72 | 4.36 | 4.68 | 52% (pricier than usual) | #3849 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on AZN.
Sign in to join the discussion.